Dr Reddy’s Laboratories (DRL) has secured regulatory approval for launch of its generic anti-histamine Allegra D24 in the US. The company, which has had to wait for more than six months to overcome the legal hurdles, is gearing up to launch the drug in both over the counter and prescription markets.
The market for Allegra D24 is estimated at $150-180 million. DRL had received US FDA nod for launching fexofenadine hydrochloride/ pseudoephedrine hydrochloride (Allegra D24) in March 2010. However, the drug’s innovator, Sanofi Aventis, blocked DRL’s plan to launch the drug by seeking an injunction in a US court in June 2010. By the time the US court had granted the injunction, DRL’s product was still not in the market.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1665.25 |
| Dr. Reddys Lab | 1220.75 |
| Cipla | 1232.90 |
| Zydus Lifesciences | 928.85 |
| Lupin | 2311.75 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: